This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Loxo Oncology, Inc.
Drug Names(s): Fibroblast Growth Factor Receptor Program, FGFR2/3, FGFR1-sparing inhibitor
Description: Loxo is designing an FGFR1-sparing inhibitor that has the potential to avoid many of the side effects that have been endemic to the FGFR class.
Array and Loxo
In July 2013, Loxo and Array BioPharma announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets.
The licensed program targets a specified novel oncogenic activating mutation. Under the terms of the agreement, Loxo will fund Array's preclinical research, providing access to Array's discovery platform and scientists, and will be responsible for target selection and conducting clinical trials. Array is eligible to receive up to $434 million in milestone payments and to receive royalties on sales of any resulting drugs. In further consideration of the rights granted to Loxo under the agreement, Array also received shares of stock in Loxo.
Partners: Array BioPharma, Inc.
FGFR Program News
Pink Sheet J&J Inks Potential $500M Deal With Astex
Additional information available to subscribers only: